Modified-Release 5-HT2C Agonist Dosage Forms for Weight Management
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current obesity treatment options are limited by lack of efficacy and unacceptable side effects, with existing drugs failing to provide sustainable weight management due to peak-to-trough plasma concentration variations and adverse effects associated with intermittent dosing.
Innovation Solution
Development of modified-release dosage forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine salts, which provide a therapeutically effective, sustained release of the 5-HT2C receptor agonist, reducing peak plasma concentrations and minimizing adverse effects while maintaining therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If immediate-release dosage forms are used, then rapid onset of action is achieved, but peak-to-trough plasma concentration variations cause unacceptable side effects and reduced tolerability
Solution Approach 1:
The patent employs modified-release technology to create periodic drug delivery, releasing the 5-HT2C agonist at controlled intervals to maintain plasma concentrations within the therapeutic window. This periodic action prevents the sharp peaks and troughs of immediate-release formulations, reducing side effects while maintaining efficacy throughout the dosing interval.
Solution Approach 2:
The modified-release formulation provides continuous therapeutic action by sustaining plasma drug concentrations within the effective range for extended periods. This continuity eliminates the fluctuations characteristic of immediate-release dosing, ensuring consistent weight management efficacy while minimizing adverse effects associated with peak concentrations.
2Ease of operation
If intermittent dosing is used, then ease of administration is improved, but peak-to-trough plasma concentration variations reduce therapeutic efficacy
Solution Approach 1:
The modified-release formulation maintains continuous therapeutic drug levels in plasma, ensuring reliable weight management efficacy. This continuous action is achieved while preserving the ease of intermittent dosing schedule, as the extended-release mechanism sustains effectiveness throughout the dosing interval without requiring frequent administration.
Solution Approach 2:
The patent modifies the release rate parameter of the drug formulation to extend the duration of action. By changing the release kinetics from immediate to modified-release, the formulation maintains therapeutic concentrations for longer periods, ensuring reliable efficacy while allowing less frequent dosing intervals.
3Reliability
If higher doses are administered to maintain therapeutic levels, then efficacy is improved, but adverse effects increase due to peak plasma concentrations
Solution Approach 1:
The modified-release formulation maintains plasma concentrations within the therapeutic window through continuous action, eliminating the need for higher peak doses. This approach sustains effective drug levels throughout the dosing interval while preventing the high peak concentrations that cause adverse effects, thereby improving the therapeutic index.
Solution Approach 2:
The patent changes the dosing parameter from high peak doses to lower, sustained doses delivered via modified-release technology. This parameter change in release kinetics maintains therapeutic efficacy while reducing peak plasma concentrations to below levels that cause adverse effects.
Data Source
AI summary
The present invention relates to methods for weight management that utilize modified-release dosage forms comprising (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine salts and crystalline forms thereof. The present invention further relates to (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine salts, crystalline forms thereof and modified-release dosage forms comprising them.